Get started

Mirati Therapeutics, Inc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

MRTX chart

Key stats

Market capitalization
2.159BUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−12.96USD

About Mirati Therapeutics, Inc

Sector
Health Technology
Industry
Biotechnology
CEO
David D. Meek
Website
mirati.com
Headquarters
San Diego
Employees
593
Founded
1995
ISIN
US60468T1051

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Ideas

Mirati Therapeutics (NASDAQ: $MRTX) Flashes Signs Of Reversal 🚦Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NS
Long
Mirati Therapeutics good news. The price will start to rise soonI spent about 3 hours researching this company and I will divide my work into 3 parts. Last report, other positive news, and why you shouldn't open long position right now. Enjoy reading. 1) Mirati Therapeutics Reports First Quarter 2021 Financial Results (May 06, 2021) The most important informati
Long
BUY to MIRATI THERAPEUTICS Hey traders, MIRATI THERAPEUTICS is in a great day of its history we can witness a new historical high. It is in a fake bullish surge with a strong buying volume at the start of the session and a hammer bear candle returned. In the TIMEFRAME M1 we can see a panic it goes to its low point which is j
MRTX - SWING ANALYSISMRTX - As per the breakout happened with the volumes also coming in it is expected to go more high from the current levels. Buy here at current price 209 Maintain stop loss around 194 Target upside 218- 234 Hit the like button to get more signals, Thanks
Long
MRTX: Sort opportunityAn intraday high potential, Back Tested Sort Analysis. We ll try to enter into the correction of the uptrend movement. DETAILS ON THE CHART NOTE: Entry range area above the entry point, is calculated upon 80% of the recorded pullback back tested past performances DISCLAIMER: This is a te
$MRTX Trade steup for Mirati Therapeutics breakoutEntry level $118 = Target price $137 = Stop loss $115 Bullish price action on the breakout. OBV indicator very strong as is the RSI Volume dominated by buyers. Short interest can still furl the rally at 14% Company profile Mirati Therapeutics, Inc. is a clinical-stage oncology company, which engages
Long
$MRTX Upgrade bullish for Mirati Therapeutics. Entry level $74 = target price $89 = Stop loss $68.80 Citi analyst Yigal Nochomovitz continues to have favorable expectations for Mirati Therapeutics' (MTRX) initial MRTX849 data in Q4 and believes that a response rate in non-small-cell lung carcinoma in line with Amgen's (AMGN) ~50% should dri
Long

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Be warned
This info isn't a recommendation for what you should personally do, so please don't take the data as investment advice. As with any trade, always look first, then leap. Read more in the Terms of Use.

Financials

Past performance
Revenue to profit conversion
Total revenue
Gross profit
EBITDA
EBIT
Net income
‪0%‬
‪0%‬
‪0%‬
‪0%‬
‪0%‬
Debt level and coverage
Earnings
Next:—
‪0‬

Trading & brokers

TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.45Fabulous
Learn more
OANDA
OANDA
Forex
4.52Great
Learn more
FOREX.com
FOREX.com
Forex
4.37Fabulous
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.35Fabulous
Learn more

See all brokers 

Gain new superpowers

Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.Learn more